baber/WOPTO huggingface dataset:
Patent AU-2005220209-B2 (AU)
Title: Immunotherapy of autoimmune disorders using antibodies which target B-cells
Inventor: HANSEN HANS J
IPC: A61P21/00
Filed: 2005-10-06
Granted: 2008-11-27
Abstract: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.
Patent AU-2005253981-B2 (AU)
Title: Antibodies against human interleukin-13 and uses therefor
Inventor: PARRIS KEVIN D
IPC: C07K16/00
Filed: 2005-06-09
Granted: 2011-10-13
Abstract: This application relates to antibodies, , humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, , a human patient, one or more IL-13-associated disorders, , respiratory disorders (, asthma); atopic disorders (, allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (, atopic dermatitis), and gastrointestinal organs (, inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.
Patent AU-2005302486-B2 (AU)
Title: Process for packaging plastic materials like hot melt adhesives
Inventor: SAJOT NICOLAS E
IPC: B65B63/08
Filed: 2005-10-28
Granted: 2011-04-14
Abstract: A method for packaging plastic material using a film to surround the material, and more particularly to a method for packaging hot melt adhesives, the resulting package formed thereby, and the film composition used therein. The method is preferably a coextrusion process for packaging a pressure sensitive hot melt adhesive by extruding a hot melt adhesive through a die orifice, and coextruding a wax-based polymeric film to surround the hot melt adhesive. The coated adhesive may then be formed into individual packaged units having a finite size and shape. The polymeric film comprises a composition having at least 25% by weight of a wax material, an enthalpy of fusion of at least about 100 J/g, and an elongation value at break of at least about 100%. Any type of hot melt adhesive formulation can be packaged or surrounded by the polymeric film in the process. Also, the specific enthalpy of fusion desired and/or elongation value at break desired for the polymeric film can be obtained by blending an appropriate amount of partially crystalline ethylene-based polymer together with a thermoplastic elastomeric block copolymer and/or an ethylene based or propylene-based elastomer.
Patent AU-2006202709-B2 (AU)
Title: Fluid coupling cap
Inventor: WELLS MICHAEL PAUL
IPC: F16L55/115
Filed: 2006-06-23
Granted: 2012-06-14
Abstract: FLUID COUPLING CAP A cap (12) for a fluid coupling (10) is provided that includes a stem member (24) adapted for insertion into the fluid coupling (10) and a cover member (26) connected to the stem member (24). The cover member (26) includes an internal cavity (28) sized to receive the fluid coupling (10) such that the fluid coupling (10) is positioned between the stem member (24) and the cover member (26). The internal cavity (28) is defined by a wall (30) having at least one of a longitudinally extending groove (32) and a longitudinally extending protrusion.
Patent AU-2006227243-B2 (AU)
Title: Dosing regimes for trans-clomiphene
Inventor: JOSEPH PODOLSKI
IPC: A61K31/138
Filed: 2006-03-17
Granted: 2011-10-27
Abstract: The present invention relates to the use of compositions comprising ?Υww-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass, limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility.
Patent AU-2006261841-B2 (AU)
Title: Pyrazole based LXR modulators
Inventor: GU XIAO HUI
IPC: A61K31/415
Filed: 2006-06-26
Granted: 2012-06-07
Abstract: Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
Patent AU-2006327969-B2 (AU)
Title: Apparatus for and method of manufacturing helically wound structures
Inventor: PETER BOOTH JOHN
IPC: B21C37/12
Filed: 2006-12-21
Granted: 2011-12-01
Abstract: An apparatus (50) for and method of manufacturing helically wound tubular structures (116) includes a rotating faceplate (74) upon which are mounted a plurality of diameter defining rollers (78) which, in operation, cause a strip material (80) to be plastically deformed into a helical winding which may be lain down in abutting or self-overlapping relationship to form said tubular structure (116).
Patent AU-2007215371-B2 (AU)
Title: Compact gym
Inventor: PIGGINS DARREN
IPC: A63B22/06
Filed: 2007-02-06
Granted: 2012-03-22
Abstract: Disclosed in this specification is a compact gym that comprises both a recumbent exercycle and a pulley system. The recumbent exercycle may be rotated by 180° to offer users a greater variety of workouts. The compact gym's various components may be folded into a cupboard for storage.
Patent AU-2007216315-B2 (AU)
Title: DNA conformation (loop structures) in normal and abnormal gene expression
Inventor: RAMADASS AROUL SELVAM
IPC: C12Q1/68
Filed: 2007-02-19
Granted: 2012-10-04
Abstract: Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.
Patent AU-2007227488-B2 (AU)
Title: Vessel closing laminate
Inventor: MCLEAN ANDREW FENWICK
IPC: B32B1/00
Filed: 2007-03-16
Granted: 2012-07-05
Abstract: A vessel closing laminate comprising: a seal laminate (1) comprising a bottom subassembfy of layers including a foil layer (5); and a seal substrate attached to the uppermost layer of the bottom subassembly of layers wherein the seal substrate has a bottom foam layer (2) and a top plastic material layer (10) and further includes a free tab (50) lying wholly within the circumference of the seal; a wax layer (11) on top of the plastic material layer of the seal substrate; and an absorbent liner (12) adhered to the plastic material layer of the seal substrate by means of the wax layer.
Patent AU-2007265157-B2 (AU)
Title: Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors
Inventor: GAI YONGHUA
IPC: A61P31/12
Filed: 2007-06-26
Granted: 2013-06-27
Abstract: The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Patent AU-2007274273-B2 (AU)
Title: Fungicide hydroximoyl-tetrazole derivatives
Inventor: GROSJEAN-COURNOYER MARIE-CLAIRE
IPC: C07D409/14
Filed: 2007-07-12
Granted: 2012-08-23
Abstract: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T represent a tetrazolyl substituent, A represents a carbo- or heterocycle, L and L represent various linking groups and Q represents a 5-membered heterocycle, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.
Patent AU-2007275658-B2 (AU)
Title: Compositions and methods for the treatment of mucositis
Inventor: PER GJORSTRUP
IPC: A61P1/04
Filed: 2007-07-19
Granted: 2011-09-01
Abstract: The invention relates to methods of treating mucositis comprising administering a compound of formula A, compound of any one of formulae 1 to 46, lipoxin compound, or oxylipin compound.
Patent AU-2007318640-B2 (AU)
Title: Microorganism capable of controlling plant diseases and plant disease-controlling agent using the microorganism
Inventor: MITSUNORI MAEDA
IPC: A01N63/27
Filed: 2007-11-06
Granted: 2011-06-30
Abstract: It is intended to provide a microorganism which has an excellent capability of controlling various plant diseases (in particular, soft rot and canker in leaf and root vegetables) while having a small environmental burden and showing an extremely low possibility of the emergence of a resistant pathogenic bacterium; a plant disease-controlling agent which contains the above-described microorganism; and a method of controlling plant diseases which comprises applying the above-described plant disease-controlling agent to a plant and/or the soil wherein the plant is grown. Use is made of a plant disease-controlling agent containing cells of that has a capability of controlling plant diseases, preferably FERM BP-10912 or its variant that has a capability of controlling plant diseases.
Patent AU-2007322340-B2 (AU)
Title: Process for making titanium dioxide
Inventor: ROSSIE ROBERT J
IPC: C01G23/07
Filed: 2007-10-05
Granted: 2011-08-04
Abstract: The disclosure relates to a process for making titanium dioxide, comprising: reacting titanium tetrachloride with oxygen by contacting the titanium tetrachloride with the oxygen in a vapor phase reactor under mixing conditions and at an elevated temperature to form a gaseous product stream containing titanium dioxide; separating the titanium dioxide from the gaseous product stream to form a process stream; analyzing the process stream to detect a concentration of titanium tetrachloride in the process stream; comparing the concentration of titanium tetrachloride detected in the process stream to an aim point concentration; and modifying the oxidation conditions to restore or maintain the concentration of titanium tetrachloride in the process stream at the aim point. In one embodiment, the process further comprises contacting the gaseous product stream with silicon tetrachloride under mixing conditions and at an elevated temperature to at least partially encapsulate the titanium dioxide with a silicon-containing compound and separating the at least partially encapsulated titanium dioxide from the gaseous product stream and analyzing the process stream to detect a concentration silicon tetrachloride for comparison to a silicon tetrachloride aim point concentration so that the conditions for silicon tetrachloride contacting can be modified to restore or maintain the concentration of silicon tetrachloride in the process stream.
Patent AU-2008202032-B2 (AU)
Title: A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
Inventor: PERABO LUCA
IPC: C12N15/09
Filed: 2008-05-07
Granted: 2012-09-20
Abstract: 5 This invention relates to a library of nucleic acids comprising a multiplicity of expressible structural genes, preferably cap genes, from an eukaryotic virus, preferably of a parvovirus.
Patent AU-2008218246-B2 (AU)
Title: System and method for in-line molten metal processing using salt reactant in a deep box degasser
Inventor: DEYOUNG DAVID H
IPC: C22B21/06
Filed: 2008-02-22
Granted: 2012-04-05
Abstract: An in-line deep box treatment of molten metal (51) wherein, Instead of gaseous Cl, a solid salt reactant containing a halide salt (e.g., MgCl) as one of its components may be injected into the molten metal along with an inert gas (typically argon) through the existing degasser impeller (42).The salt flux may be metered into the inert gas stream at a controlled rate. A salt injector flux tank (44) may be retrofitted to current rotary degassing equipments without requiring a specialized rotor (50) design or changes in the degasser unit design. Using the halide salt-based solid flux, the benefits of alkali, alkaline earth, and inclusion removal may be achieved without the industrial hygiene, environmental, and safety issues associated with storing and using the gaseous and hazardous Cl during molten metal degassing.
Patent AU-2008226762-B2 (AU)
Title: Metallized films
Inventor: TROUILHET YVES M
IPC: B32B27/32
Filed: 2008-03-17
Granted: 2012-08-30
Abstract: Provided herein are multilayer film structures that may be used in packaging applications, for example. The multilayer film structures include a first metallized thermoplastic film and a second thermoplastic film. These first and second films are joined directly to each other over at least a portion of their surface area to form a laminate having the structure "first thermoplastic film/metallic layer/second thermoplastic film". The thermoplastic layers of the films may be the same or different and comprise one or more ethylene acid copolymers or ionomers thereof. The first metallized thermoplastic film has an optical density of 3 or less. When the first metallized thermoplastic film and the second thermoplastic film are joined by heat sealing to form the structure "thermoplastic film/metallic layer/ thermoplastic film", its internal seal strength is at least about 4 N/15 mm.
Patent AU-2008232709-B2 (AU)
Title: Stitched polypeptides
Inventor: VERDINE GREGORY L
IPC: C07K14/43
Filed: 2008-03-28
Granted: 2014-05-29
Abstract: The present invention provides inventive stitched polypeptides, pharmaceutical compositions thereof, and methods of making and using inventive stitched polypeptides.
Patent AU-2008237592-B2 (AU)
Title: Improvements in Articulated Vehicles
Inventor: RIGOLI PRINCE LITTLE JOSEPH
IPC: B60P1/16
Filed: 2008-10-29
Granted: 2014-04-03
Abstract: A trailer for use in an articulated vehicle. The trailer comprises first and second parts movable longitudinally relative to each other whereby to place the trailer into load transporting and load handling positions. The first 5 part has hook lift means secured thereto, and the second part comprises road wheels and a fifth wheel assembly adapted for articulating connection of a further trailer behind said trailer. In the load handling configuration the fifth wheel assembly lies below said hook lift means so that the hook lift means can lift a load from a ground surface onto said first part while clearing the fifth 10 wheel assembly. In the load transporting configuration the fifth wheel assembly lies below and behind said hook lift means and the load so that the further trailer can be secured to said fifth wheel assembly for normal articulation thereon. too 4c)
Patent AU-2008254385-B2 (AU)
Title: System and technique to remove perturbation noise from seismic sensor data
Inventor: OZDEMIR AHMET KEMAL
IPC: G01V1/38
Filed: 2008-03-31
Granted: 2014-02-27
Abstract: A technique includes obtaining a noise measurement, which is acquired by a seismic sensor while in tow. Based on the noise measurement, a compensation for at least one of an alignment of the sensor and a calibration of the sensor is determined.
Patent AU-2008266007-B2 (AU)
Title: System and method for tracking personnel and equipment
Inventor: BLAYLOCK PAUL R
IPC: G01S1/00
Filed: 2008-06-13
Granted: 2012-10-04
Abstract: A system for tracking personnel and equipment in hazardous environments in pre or post-accident situations includes an intrinsically safe tracking tag and an intrinsically safe reader system. The intrinsically safe tracking tag transmits identification and status information to the intrinsically safe reader system, which includes a plurality of intrinsically safe antennas and a hub cable driver. In one embodiment, antennas are located at known positions in the hazardous environment and connected via a redundant, wired-mesh topology. The wired-mesh topology also allows more flexible antenna placement than line-of-sight wireless-mesh systems. The hub cable driver provides intrinsically safe power to and communication with the antennas using communication cables, receives data signals from the antennas, and transmits the data signals to a server. The server stores the data signals in a storage device and is connected to a workstation. The workstation retrieves the stored data to track persons or equipment.
Patent AU-2008274298-B2 (AU)
Title: Apparatus and method for determining the necessary correction of defective vision of an eye
Inventor: CABEZA-GUILLEN JESUS-MIGUEL
IPC: A61B3/103
Filed: 2008-07-08
Granted: 2013-12-05
Abstract: The invention relates to a method for determining the necessary optical correction (2) of the defective vision of an eye (1). According to the invention,the focal area (8) of a light beam (3) passing through the eye (1) is optimized in the region of the retina (6) of the eye (1) by means of optical correction (2). The invention further relates to an apparatus suitable for implementation of the method.
Patent AU-2008307145-B2 (AU)
Title: Markers of endothelial cells and uses thereof
Inventor: LESKE ANNABELL FRANCIS
IPC: C12Q1/00
Filed: 2008-10-02
Granted: 2014-07-10
Abstract: Use of a beta tubulin isotype that is differentially expressed between activated endothelial cells and quiescent endothelial cells for identifying an agent which inhibits or promotes angiogenesis and/or vascular function.
Patent AU-2009206489-B2 (AU)
Title: Method of selecting antioxidants for use in topically applied compositions
Inventor: BEASLEY DONATHAN G
IPC: A61Q17/04
Filed: 2009-01-21
Granted: 2014-10-02
Abstract: Antioxidant-containing compositions and methods for confirming antioxidant activity of a composition formulated for topical application to skin. Methods for testing a composition for ability to inhibit both ultraviolet radiation-induced lipid peroxidation on skin and ultraviolet radiation-induced reactive oxygen species formation in the stratum corneum. Compositions and methods for treating and preventing photodamage to skin.
Patent AU-2009212262-B2 (AU)
Title: 1D05 PCSK9 antagonists
Inventor: WOOD DANA D
IPC: C12N15/13
Filed: 2009-02-06
Granted: 2015-04-09
Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
Patent AU-2009231822-B2 (AU)
Title: Determinative segmentation resegmentation and padding in radio link control (RLC) service data units (SDU)
Inventor: HO SAI YIU DUNCAN
IPC: H04W28/06
Filed: 2009-03-31
Granted: 2013-03-28
Abstract: A transmission entity (e.g., user equipment (UE)) is expected to reduce the segmentation of Radio Link Control (RLC) Service Data Units (SDUs) while also minimizing padding. Signaling or provisioning of a constraint value such as a maximum padding amount or minimum segmentation size is employed in a determinative way in the UE to balance these objectives. A receiving entity (e.g., evolved base node (eNB)) benefits from being able to signal these parameters, whose application to RLC instances can discriminate between data and signaling radio bearers. Compliance can also be voluntary, such as the network entity employing at least a portion of the same approach on the downlink.
Patent AU-2009234090-B2 (AU)
Title: Lithofacies classification system and method
Inventor: HRUSKA MARINA M
IPC: G01V11/00
Filed: 2009-03-27
Granted: 2015-02-19
Abstract: A method of analyzing characteristics of a subterranean formation includes applying a wavelet transform to measured data or to derived data obtained from the measured data, the measured data obtained by measuring a physical property at each of a plurality of positions in a borehole that penetrates the subterranean formation; selecting one or more scales for analyzing wavelet coefficients; performing a segmentation of the data; calculating a distribution of wavelet coefficients for each scale, for one or more spatial directions of wavelet transform application, for the wavelet transform of the data and for each segment that belongs to the portion on which the wavelet transform has been calculated; and for each segment, analyzing a distribution of the data and the distribution of the wavelet coefficients for each scale in terms of their overlap with corresponding distributions of training samples to produce a geological interpretation of the subterranean formation.
Patent AU-2009243734-B2 (AU)
Title: Granulate comprising escitalopram oxalate
Inventor: LIPSDORF ANTJE
IPC: A61K9/16
Filed: 2009-05-05
Granted: 2014-02-27
Abstract: The invention relates to a granulate comprising escitalopram oxalate having an average particle size of less than 100 μm and at least one filler. The invention further relates to a method of producing that granulate and also to a tablet or capsule comprising that granulate and/or obtained by compressing that granulate to form a tablet or by filling that granulate into a capsule shell. Finally, the invention relates to the use of that granulate and/or tablet or capsule in the treatment or prevention of a disorder from the spectrum of depressive disorders.
Patent AU-2009247077-B2 (AU)
Title: Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
Inventor: CHANG HYE-JIN
IPC: A61K31/19
Filed: 2009-05-14
Granted: 2014-04-17
Abstract: There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anticonvulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray- administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant. Also, the transnasal anticonvulsive pharmaceutical composition may be useful to allow the poorly soluble anticonvulsant to show the improved viscosity and/or enhanced solubility in order to effectively deliver the poorly soluble anticonvulsant at a therapeutic dose.